Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
A.T. Holdings II
Lausanne, Switzerland
- Ownership
- Private
- Development stage
- Other
01
Overview
A.T. Holdings II is a private Swiss holding company organized as a Sàrl that appears to function as an investment and shareholder vehicle rather than an operating biotechnology or healthcare company. Public SEC filings identify it as a significant shareholder of ADC Therapeutics and state that it is ultimately wholly owned by Auven Therapeutics Holdings, an investment organization. The available evidence indicates that A.T. Holdings II does not itself develop drug candidates, provide healthcare products or services, or operate a therapeutic pipeline. Instead, its relevance to life sciences is indirect, through ownership interests in portfolio companies such as ADC Therapeutics.
- Industry
- Investors
Beyond the preview
Go deeper on A.T. Holdings II.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A.T. Holdings II.